Heart-health biotech company Kardigan Inc. completes an upsized initial public offering that raises $400 million. Multiple reports say the IPO is priced at $16 per share, at the top of the company’s marketed price range. The offering is described as an increase from the original size, though the exact initial target is not provided in the excerpts. Following the IPO pricing, Kardigan shares begin trading with modest gains in the secondary market. Bloomberg reports that the stock rises nearly 2% in its trading debut, indicating an early positive reaction to the newly issued shares. The company is characterized by outlets as focused on cardiovascular and heart health biotherapeutics. Across the reports, the main agreed points are the final gross proceeds, the pricing level relative to the marketed range, and the near-term share movement on debut. No additional details about use of proceeds, underwriting, or the company’s specific clinical programs are included in the provided source summaries.